Literature DB >> 9149373

Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.

D F Lewis1, P J Eddershaw, P S Goldfarb, M H Tarbit.   

Abstract

1. A molecular model of CYP2D6 has been constructed from the bacterial form CYP102 via a homology alignment between the CYP2D subfamily and CYP102 protein sequences. 2. A number of typical CYP2D6 substrates are shown to fit the putative active site of the enzyme, as can the specific inhibitor quinidine. 3. Some of the allelic variants in CYP2D6, which give rise to genetic polymorphisms in 2D6-mediated metabolism, can be rationalized in terms of their position within the active site region. 4. The results of site-directed mutagenesis experiments are consistent with the CYP2D6 model generated from the CYP102 crystal structure. 5. The possibility of an alternative orientation within the active site may explain the CYP2D6-mediated metabolism of relatively large-sized substrates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149373     DOI: 10.1080/004982597240497

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.

Authors:  Gudrun Hefner; Stefan Unterecker; Mohamed E E Shams; Margarete Wolf; Tanja Falter; Ekkehard Haen; Christoph Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2015-05-05       Impact factor: 3.575

2.  Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.

Authors:  L Muratori; M Parola; A Ripalti; G Robino; P Muratori; G Bellomo; R Carini; M Lenzi; M P Landini; E Albano; F B Bianchi
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

3.  Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.

Authors:  G P Hayhurst; J Harlow; J Chowdry; E Gross; E Hilton; M S Lennard; G T Tucker; S W Ellis
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

4.  Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants.

Authors:  Youbin Tu; Rahul Deshmukh; Meena Sivaneri; Grazyna D Szklarz
Journal:  Drug Metab Dispos       Date:  2008-08-14       Impact factor: 3.922

Review 5.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

6.  Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s.

Authors:  David F V Lewis
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 7.  "Commandeuring" Xenobiotic Metabolism: Advances in Understanding Xenobiotic Metabolism.

Authors:  Barbara M A van Vugt-Lussenburg; Liliana Capinha; Jelle Reinen; Martijn Rooseboom; Michel Kranendonk; Rob C A Onderwater; Paul Jennings
Journal:  Chem Res Toxicol       Date:  2022-06-29       Impact factor: 3.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.